公开(公告)号：US07365061B2

公开(公告)日：2008-04-29

申请号：US11273167

申请日：2005-11-14

申请人： Philip M. Sher ,  Gang Wu ,  Wei Meng ,  Alexandra A. Nirschl ,  William N. Washburn ,  Terry Stouch

发明人： Philip M. Sher ,  Gang Wu ,  Wei Meng ,  Alexandra A. Nirschl ,  William N. Washburn ,  Terry Stouch

IPC分类号： A61K31/404 ,  A61K31/454 ,  A61K31/397 ,  C07D209/04 ,  C07D205/04 ,  C07D401/08

CPC分类号： C07D209/42 ,  C07D235/24 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D491/04 ,  C07D493/08 ,  C07D495/04

摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, X, Y and Z are defined herein.

摘要翻译： 提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管 与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件 包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。 这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1，R 2，X，Y和Z在本文中定义。

公开(公告)号：US20070165620A1

公开(公告)日：2007-07-19

申请号：US10580722

申请日：2004-11-04

申请人： Yueheng Li ,  Li Sun ,  Gang Wu

发明人： Yueheng Li ,  Li Sun ,  Gang Wu

IPC分类号： H04L12/50

CPC分类号： H04B1/7105 ,  H04B2201/709709

摘要： A method is proposed for supporting downlink JD (joint detection) in a TDD CDMA communication network system, comprising steps of: judging whether the CAI (code allocation information) in a downlink timeslot will change in the next TTI (transmission time interval); if the CAI will change, inserting the changed CAI as a specific control information into a specified field in the traffic burst in the downlink timeslot corresponding to current TTI; sending the traffic burst containing the specific control information to each UE (user equipment) in the downlink timeslot via a downlink channel.

摘要翻译： 提出了一种支持TDD CDMA通信网络系统中的下行链路JD（联合检测）的方法，包括以下步骤：判断下行时隙中的CAI（码分配信息）是否在下一个TTI（传输时间间隔）内发生变化; 如果CAI将改变，则将改变的CAI作为特定控制信息插入到对应于当前TTI的下行链路时隙中的业务突发中的指定字段中; 经由下行链路信道向下行链路时隙中的每个UE（用户设备）发送包含特定控制信息的业务突发。

公开(公告)号：US20070004772A1

公开(公告)日：2007-01-04

申请号：US11454322

申请日：2006-06-16

申请人： Chongqing Sun ,  Philip Sher ,  Gang Wu ,  William Ewing ,  Yanting Huang ,  Taekyu Lee ,  Natesan Murugesan ,  Richard Sulsky

发明人： Chongqing Sun ,  Philip Sher ,  Gang Wu ,  William Ewing ,  Yanting Huang ,  Taekyu Lee ,  Natesan Murugesan ,  Richard Sulsky

IPC分类号： C07D471/02 ,  A61K31/4745

CPC分类号： C07D471/04

摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

摘要翻译： 本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物，以及使用式I化合物单独和与一种或多种 其他治疗剂。 该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3， 本文描述了R 4和R 5。

公开(公告)号：US07096022B2

公开(公告)日：2006-08-22

申请号：US10266776

申请日：2002-10-08

申请人： Xia Gao ,  Gang Wu

发明人： Xia Gao ,  Gang Wu

IPC分类号： H04Q7/20

CPC分类号： H04W28/26 ,  H04W36/0066 ,  H04W80/00

摘要： A method, system, and business model are disclosed for supporting handover between a mobile host and a corresponding node located in a heterogeneous network. Handover paths are established to accommodate a plurality of quality of service properties. Admission control is performed that considers the established handover paths and an established first reservation path. Gateways are contacted to determine a handover path to use. The determined handover path is used to support vertical handover. A second reservation path is established while maintaining the first reservation path and the handover path.

公开(公告)号：US07020440B2

公开(公告)日：2006-03-28

申请号：US10318803

申请日：2002-12-13

申请人： Fujio Watanabe ,  Gang Wu

发明人： Fujio Watanabe ,  Gang Wu

IPC分类号： H04Q7/20

CPC分类号： H04W64/00

摘要： A location update system for updating a location of a mobile terminal. The system includes a paging area with a mobile terminal present within the paging area, a domain area with the mobile terminal present within the domain area and a paging location update server that is communication with the mobile terminal and updates a location of the mobile terminal and updates the domain area.

摘要翻译： 一种用于更新移动终端的位置的位置更新系统。 该系统包括：寻呼区域，其中存在于寻呼区域内的移动终端;移动终端存在于域区域内的域区域;以及寻呼位置更新服务器，其与移动终端通信并更新移动终端的位置， 更新域名区域。

公开(公告)号：US06515117B2

公开(公告)日：2003-02-04

申请号：US10151436

申请日：2002-05-20

申请人： Bruce Ellsworth ,  William N. Washburn ,  Philip M. Sher ,  Gang Wu ,  Wei Meng

发明人： Bruce Ellsworth ,  William N. Washburn ,  Philip M. Sher ,  Gang Wu ,  Wei Meng

IPC分类号： C07H1520

CPC分类号： C07C43/225 ,  A61K31/70 ,  A61K31/7034 ,  A61K45/06 ,  C07C45/46 ,  C07C49/84 ,  C07H7/04 ,  C07H15/203 ,  A61K2300/00

摘要： An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

摘要翻译： 提供具有式A的SGLT2抑制化合物还用于治疗糖尿病和相关疾病，其使用单独的SGLT2抑制量的上述化合物或与另一种抗糖尿病剂或其它治疗剂组合。

公开(公告)号：US06414126B1

公开(公告)日：2002-07-02

申请号：US09679027

申请日：2000-10-04

申请人： Bruce Ellsworth ,  William N. Washburn ,  Philip M. Sher ,  Gang Wu ,  Wei Meng

发明人： Bruce Ellsworth ,  William N. Washburn ,  Philip M. Sher ,  Gang Wu ,  Wei Meng

IPC分类号： C07H1520

CPC分类号： C07H15/203 ,  A61K31/70 ,  A61K31/7034 ,  A61K45/06 ,  C07C43/225 ,  C07C45/46 ,  C07C49/84 ,  A61K2300/00

摘要： SGLT2 inhibiting compounds are provided having the formula where R1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CN, —CO2R5b, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5h)R6d, —CONR6R6a, —NHCOR5c, —NHSO2R5d, —NHSO2Aryl, Aryl, —SR5e, —SOR5f, —SO2R5g, —SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl; R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH2)n where n is 0-3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

摘要翻译： 提供的SGLT2抑制化合物具有式R 1，R 2和R 2a独立地是氢，OH，OR 5，低级烷基，CF 3，OCHF 2，OCF 3，SR 5i或卤素，或者R 1，R 2和R 2a中的两个与它们相同的碳 R 3和R 4独立地是氢，OH，OR 5 a，OA基，OCH 2芳基，低级烷基，环烷基，CF 3，-OCHF 2，-OCF 3，卤素，-CN，-CO 2 R 5b ，-CO 2 H，-COR 6 b，-CH（OH）R 6c，-CH（OR 5h）R 6d，-CONR 6 R 6 a，-NHCOR 5 C，-NHSO 2 R 5d，-NHSO 2芳基，芳基，-SR 5e，-SOR 5 f，-SO 2 R 5，-SO 2芳基或五 ，六或七元杂环，或R 3和R 4与它们所连接的碳一起形成环状五，六或七元碳环或杂环; R5，R5a，R5b，R5c，R5d，R5e，R5f，R5g，R5h R5i独立地为低级烷基; R6，R6a，R6b，R6c和R6d独立地为氢，烷基，芳基，烷基芳基或环烷基，或R6和R6a与它们所连接的氮一起 形成五至六元或七元杂环; A为O，S，NH或（CH2）n，其中n为0-3。另外还提供了一种用于治疗糖尿病和相关疾病的方法，该方法采用上述的SGLT2抑制量 化合物单独或与另一种抗糖尿病剂或其它治疗剂组合。

公开(公告)号：US08889051B2

公开(公告)日：2014-11-18

申请号：US13406441

申请日：2012-02-27

申请人： Jinxiang Chen ,  Zhishen Wu ,  Gang Wu ,  Juan Xie ,  Hong Zhu

发明人： Jinxiang Chen ,  Zhishen Wu ,  Gang Wu ,  Juan Xie ,  Hong Zhu

IPC分类号： B29C33/52 ,  B29C45/44 ,  B29C33/30 ,  B29L31/60

CPC分类号： B29C33/52 ,  B29C33/302 ,  B29C45/4457 ,  B29L2031/608 ,  Y10S425/012

摘要： A mold and a method for integrally manufacturing a functional cored slab and a solid slab with a polygonal grid honeycomb structure. The mold for manufacturing the cored slab comprises a female mold and multiple male molds which are provided in the female mold. The male molds include polygonal cylinders capable of melting, dissolving, or vaporizing. A clearance exists between at least one pair of adjacent polygonal cylinders. The mold for manufacturing the solid slab is provided with a male mold main-body of polygonal cylinders which share the same shape and amount as the polygonal grids. The male mold main-body, which is made of one of the functional materials including sound insulating materials, flame retardant materials, and thermal insulating materials, is located in the frame-like female mold having a bottom plate. Clearances are provided between the adjacent male mold bodies. A casting method is adopted when manufacturing the slabs.

摘要翻译： 一种用于整体制造功能性芯板和具有多边形网格蜂窝结构的实心板的模具和方法。 用于制造芯板的模具包括阴模和设置在阴模中的多个阳模。 阳模包括能熔化，溶解或蒸发的多边形圆柱体。 在至少一对相邻的多边形柱体之间存在间隙。 用于制造实心板的模具设置有与多边形网格具有相同形状和数量的多边形柱体的阳模主体。 由具有隔音材料，阻燃材料和绝热材料的功能材料之一制成的阳模主体位于具有底板的框架状阴模中。 在相邻的阳模体之间设置间隙。 制造板坯时采用铸造方法。

公开(公告)号：US08761288B2

公开(公告)日：2014-06-24

申请号：US12919374

申请日：2009-02-26

申请人： Wei Miao ,  Min Huang ,  Shindong Zhou ,  Gang Wu

发明人： Wei Miao ,  Min Huang ,  Shindong Zhou ,  Gang Wu

IPC分类号： H04L1/02 ,  H04B7/04 ,  H04L1/00

CPC分类号： H04B7/0417 ,  H04B7/0465 ,  H04L1/0003 ,  H04L1/0009

摘要： A multiuser downlink multiple-input multiple-output (MIMO) system with limited channel information feedback includes an error-free channel vector quantization scheme. Each user has multiple antennas, and the base station includes a matching number of antennas. Each MIMO channel is measured at the terminus end of a corresponding user, and used to obtain the channel state information at the receiver (CSIR). A few data bits of CSIR information are feed back to the base station through the limited feedback channels. The base station collects all these CSIR feedback data bits into a CSI at the transmitter (CSIT). The CSIT is used to determine which users are served, and how to configure a corresponding multi-user precoder. The user data channels will later all be transmitted through such precoder. A codebook of channel quantization vectors is pre-defined and distributed amongst the base station and all the users.

摘要翻译： 具有有限信道信息反馈的多用户下行链路多输入多输出（MIMO）系统包括无差错信道矢量量化方案。 每个用户具有多个天线，并且基站包括匹配数量的天线。 在相应用户的终端测量每个MIMO信道，并用于在接收机（CSIR）获得信道状态信息。 CSIR信息的几个数据位通过有限反馈信道反馈给基站。 基站将所有这些CSIR反馈数据位收集到发射机（CSIT）的CSI中。 CSIT用于确定哪些用户被服务，以及如何配置相应的多用户预编码器。 稍后将通过这样的预编码器传送用户数据信道。 信道量化矢量码本被预定义并分布在基站和所有用户之间。

公开(公告)号：US20130307029A1

公开(公告)日：2013-11-21

申请号：US13989771

申请日：2011-12-31

申请人： Mingsheng Xu ,  Hongzheng Chen ,  Gang Wu ,  Minmin Shi ,  Mang Wang

发明人： Mingsheng Xu ,  Hongzheng Chen ,  Gang Wu ,  Minmin Shi ,  Mang Wang

IPC分类号： G01N27/414

CPC分类号： G01N27/4145

摘要： A high-resolution biosensor for analysis of biomolecules is provided. The high-resolution biosensor comprises a functional unit comprising a conducting material with an atomic-scale thickness and a micro-nano fluidic system unit. The functional unit is capable of achieving a resolution required to detect a characteristic of individual biomolecule, and the micro-nano fluidic system unit is capable of controlling the movement and conformation of the biomolecule investigated. The functional unit comprises a first insulating layer, conducting functional layer, a second insulating layer, and a nanopore extending through the full thickness of the functional unit. The micro-nano fluidic system unit comprises a first electrophoresis electrode or micropump, a first fluidic reservoir, a second fluidic reservoir, a second electrophoresis electrode or micropump, and micro-nanometer separation channels. The nanopore connects to the micro-nanometer separation channels. Interactions between the biomolecule and conducting functional layer occur as the biomolecule translocates through the nanopore of the functional unit.

摘要翻译： 提供了用于分析生物分子的高分辨率生物传感器。 高分辨率生物传感器包括具有原子尺度厚度的导电材料和微纳米流体系统单元的功能单元。 该功能单元能够实现检测各个生物分子的特征所需的分辨率，微纳米流体系统单元能够控制所研究的生物分子的运动和构象。 功能单元包括第一绝缘层，导电功能层，第二绝缘层和延伸穿过功能单元的整个厚度的纳米孔。 微纳米流体系统单元包括第一电泳电极或微型泵，第一流体储存器，第二流体储存器，第二电泳电极或微型泵以及微纳米分离通道。 纳米孔连接到微纳米分离通道。 当生物分子通过功能单元的纳米孔移位时，生物分子和导电功能层之间的相互作用发生。